Jeffery Allen, MD
Neurology · Minneapolis, MNNPI 1982894010
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by CSL Behring at 27.3% of the total. Among neurology clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 832 payments — averaging $1353.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$307K
- Argenx US, Inc.$270K
- AstraZeneca$181K
- Takeda Pharmaceuticals U.S.A., Inc.$153K
- Alnylam Pharmaceuticals Inc.$82K
- Sanofi$38K
- plus $95K from 13 others
Across 41 payments — averaging $9854.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$220K
- Sanofi US Services Inc.$92K
- Argenx US, Inc.$46K
- Takeda Pharmaceuticals U.S.A., Inc.$42K
- UCB, Inc.$3K
- Octapharma USA, Inc.$1K
What the payments were for
- Consulting fees$293,73526%
- Speaking & faculty fees$659,95959%
- Travel & lodging$161,22614%
- Food & beverage$10,8511%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 222 | $307,093 |
| Argenx US, Inc. | 154 | $269,995 |
| AstraZeneca(2 entities) | 170 | $180,904 |
| Takeda Pharmaceuticals U.S.A., Inc. | 100 | $153,233 |
| Alnylam Pharmaceuticals Inc. | 88 | $81,720 |
| Sanofi | 16 | $38,376 |
| Johnson & Johnson | 16 | $24,535 |
| Akcea Therapeutics, Inc. | 32 | $22,819 |
| EMD Serono Research & Development Institute, Inc. | 2 | $10,611 |
| Amgen | 5 | $9,014 |
| Octapharma USA, Inc. | 14 | $8,077 |
| Grifols USA, LLC | 2 | $7,000 |
| Grifols Shared Services North America, Inc. | 2 | $5,700 |
| Biocryst Pharmaceuticals, Inc. | 1 | $2,320 |
| Daiichi Sankyo Inc. | 1 | $1,063 |
| Vertex | 3 | $1,020 |
| Janssen Research & Development, LLC | 2 | $1,000 |
| Sanofi US Services Inc. | 1 | $915 |
| Pfizer | 1 | $450 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,125,844 in reported general payments places this provider in the 95th percentile of 434 neurology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 59 | $887,503 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 12 | $133,833 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $27,876 |
| Mycophenolate Mofetil | 75 | $6,098 |
| Pyridostigmine Bromide | 67 | $3,559 |
| Gabapentin | 103 | $1,439 |
| Mexiletine Hcl | 11 | $1,257 |
| Pregabalin | 27 | $582 |
| Duloxetine Hcl | 12 | $530 |
| Prednisone | 63 | $477 |
| Baclofen | 12 | $235 |
| Sertraline Hcl | 12 | $129 |
| Propranolol Hcl | 13 | $126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen, Hizentra | $307,093 | $1,021,33771 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $153,233 | $27,87612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 434 neurology providers in Minnesota.
Other neurology in Minneapolis
- Jerrold VitekMinneapolis$97K
- Leonardo Brito de AlmeidaMinneapolis$80K
- Kamaskshi LakshminarayanMinneapolis$64K
- Sanjay SinghMinneapolis$42K
- Elizabeth NeilMinneapolis$26K
- Allyson ConnorMinneapolis$23K
- Kelsey JensenMinneapolis$22K
- Javier Suarez OliverosMinneapolis$22K
- Ilo LeppikMinneapolis$18K
- Kristine DomingoMinneapolis$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.